Rigel Pharmaceuticals, Inc.
IRAK inhibitors and method for making and using
Last updated:
Abstract:
Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
Status:
Grant
Type:
Utility
Filling date:
25 Oct 2017
Issue date:
6 Aug 2019